Business, energy, technology, markets and global industry news from Business News Today

targeted therapy

PharmaDeviceNews targeted therapy
Representative image of oncology researchers reviewing cancer scans and molecular data, reflecting Ranok Therapeutics’ RNK08954 Phase 1a results and the accelerating race to develop KRAS G12D targeted therapies for pancreatic cancer, lung cancer and other advanced solid tumours.
Pharma & Biotech

Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up

KRAS G12D was long seen as nearly untouchable. Ranok’s RNK08954 now has early clinical data, but the pivotal test is still ahead.

Read More
Representative image of an oncology researcher reviewing colorectal cancer scan data, reflecting Pfizer’s Braftovi regimen update in BRAF V600E-mutant metastatic colorectal cancer.
Pharma & Biotech

Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?

Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.

Read More
Representative image of oncology researchers reviewing lung cancer imaging and genomic data, reflecting Kelun-Biotech’s lunbotinib fumarate Phase II results in RET fusion-positive non-small cell lung cancer.
Pharma & Biotech

Kelun-Biotech’s ASCO 2026 data strengthens China’s next wave of targeted cancer drugs

Kelun-Biotech’s RET lung cancer data looks strong, but CNS durability and global competition will decide its real impact.

Read More
Pharma & Biotech

Can Thermo Fisher help Nuvation Bio scale Ibtrozi supply for ROS1-positive NSCLC?

Rare cancer drugs need more than FDA approval. Nuvation Bio’s Ibtrozi test now shifts to U.S. supply reliability and launch execution.

Read More
Pharma & Biotech

FDA approval of Bizengri gives Partner Therapeutics a broader rare-oncology opportunity

Rare cancer biology met regulatory urgency. Bizengri’s approval tests whether precision oncology can reach tiny patient subsets fast.

Read More
Representative image of a clinician reviewing oncology imaging and molecular testing data, reflecting how BIZENGRI’s FDA approval could advance targeted treatment for NRG1 fusion-positive cholangiocarcinoma.
Pharma & Biotech

Why Partner Therapeutics’ BIZENGRI approval matters beyond cholangiocarcinoma

Rare cancer biology is becoming commercially actionable. BIZENGRI’s FDA approval puts NRG1 fusion testing under sharper scrutiny.

Read More
Pharma & Biotech

AbbVie Inc. secures strategic option on Kestrel Therapeutics Inc. amid KRAS innovation race

A new pan-KRAS approach enters Phase 1 backed by AbbVie Inc. Discover the implications for oncology pipelines and KRAS-driven cancers.

Read More
Pharma & Biotech

How Florida Cancer Specialists contributed to a study that may change KRAS G12D cancer treatment

Setidegrasib showed early activity in KRAS G12D lung and pancreatic cancers. Read why the Phase 1 signal could matter for oncology’s next target.

Read More
Pharma & Biotech

Dizal’s Zegfrovy challenges chemo dominance in rare EGFR lung cancer mutation

Zegfrovy Phase 3 results could redefine EGFR exon20ins lung cancer treatment. Discover what this means for frontline therapy and future care strategies.

Read More
Pharma & Biotech

Could IDEAYA Biosciences challenge current standards in metastatic uveal melanoma with darovasertib?

IDEAYA Biosciences nears darovasertib trial data. Discover how results could reshape metastatic uveal melanoma treatment strategies.

Read More